title: Strategies to eradicate minimal residual disease in small cell lung cancer: high-dose chemotherapy with autologous bone marrow transplantation, matrix metalloproteinase inhibitors, and BEC2 plus BCG vaccination.
abstract: In the last 25 years, treatment for small cell lung cancer (SCLC) has improved with advances in chemotherapy and radiotherapy. Standard chemotherapy regimens can yield 80% to 90% response rates and some cures when combined with thoracic irradiation in limited-stage patients. Nonetheless, small cell lung cancer has a high relapse rate due to drug resistance; this has resulted in poor survival for most patients. Attacking this problem requires a unique approach to eliminate resistant disease remaining after induction therapy. This review will focus on three potential strategies: high-dose chemotherapy with autologous bone marrow transplantation, matrix metalloproteinase inhibitors, and BEC2 plus BCG vaccination.
authors.affiliation: Department of Medicine, Memorial Sloan-Kettering Cancer Center, Cornell University Medical College, New York, NY 10021, USA.
authors.forename: L M
authors.initials: LM
authors.lastname: Krug
authors.forename: S C
authors.initials: SC
authors.lastname: Grant
authors.forename: V A
authors.initials: VA
authors.lastname: Miller
authors.forename: K K
authors.initials: KK
authors.lastname: Ng
authors.forename: M G
authors.initials: MG
authors.lastname: Kris
mesh_terms: D000911:Antibodies, Monoclonal / Q000276:immunology / Q000378:metabolism; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001500:BCG Vaccine / Q000627:therapeutic use; D016026:Bone Marrow Transplantation; D018288:Carcinoma, Small Cell / Q000628:therapy*; D002986:Clinical Trials as Topic; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D005732:Gangliosides / Q000276:immunology / Q000378:metabolism; D006801:Humans; D008175:Lung Neoplasms / Q000628:therapy*; D061965:Matrix Metalloproteinase Inhibitors; D018365:Neoplasm, Residual / Q000628:therapy
chemical_list: D000911:Antibodies, Monoclonal; D001500:BCG Vaccine; D004791:Enzyme Inhibitors; D005732:Gangliosides; D061965:Matrix Metalloproteinase Inhibitors; C026226:ganglioside, GD3